KR20000005539A - Dhea복합요법 - Google Patents
Dhea복합요법Info
- Publication number
- KR20000005539A KR20000005539A KR1019980708339A KR19980708339A KR20000005539A KR 20000005539 A KR20000005539 A KR 20000005539A KR 1019980708339 A KR1019980708339 A KR 1019980708339A KR 19980708339 A KR19980708339 A KR 19980708339A KR 20000005539 A KR20000005539 A KR 20000005539A
- Authority
- KR
- South Korea
- Prior art keywords
- interleukin
- synthesis
- compounds
- receptor molecule
- polyclonal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1569596P | 1996-04-17 | 1996-04-17 | |
US60/015,695 | 1996-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20000005539A true KR20000005539A (ko) | 2000-01-25 |
Family
ID=21773003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980708339A KR20000005539A (ko) | 1996-04-17 | 1997-04-17 | Dhea복합요법 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0901375A1 (no) |
JP (1) | JP2000508654A (no) |
KR (1) | KR20000005539A (no) |
CN (1) | CN1216470A (no) |
AU (1) | AU734807B2 (no) |
CA (1) | CA2251733A1 (no) |
IL (1) | IL126623A0 (no) |
NO (1) | NO984851L (no) |
WO (1) | WO1997038695A1 (no) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
JP2002531407A (ja) * | 1998-11-24 | 2002-09-24 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | マラリアの治療並びにアフリカトリパノソーマ感染症及びアメリカトリパノソーマ感染症の治療における17−ケトステロイド化合物及びその誘導体、代謝物及び前駆体の使用 |
NZ511721A (en) * | 1998-11-24 | 2004-07-30 | Hollis Eden Pharmaceuticals | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses |
AU1923500A (en) * | 1998-11-27 | 2000-06-19 | Hollis-Eden Pharmaceuticals, Inc. | Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis |
EP2983705A2 (en) * | 2013-04-10 | 2016-02-17 | Skau Aps | Use of immune suppressive peptides as adjuvants |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
IE882585L (en) * | 1988-08-25 | 1990-02-25 | Prendergast Patrick T | Viral treatment system |
IL94878A (en) * | 1989-06-28 | 2003-01-12 | Schering Corp | Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same |
US5231012A (en) * | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
HU220103B (hu) * | 1992-08-20 | 2001-10-28 | Schering-Plough Corp. | IL-10 új alkalmazása |
US5449688A (en) * | 1993-03-30 | 1995-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating chronic inflammatory diseases |
-
1997
- 1997-04-17 WO PCT/IB1997/000414 patent/WO1997038695A1/en not_active Application Discontinuation
- 1997-04-17 IL IL12662397A patent/IL126623A0/xx unknown
- 1997-04-17 EP EP97917365A patent/EP0901375A1/en not_active Withdrawn
- 1997-04-17 CA CA002251733A patent/CA2251733A1/en not_active Abandoned
- 1997-04-17 KR KR1019980708339A patent/KR20000005539A/ko not_active Application Discontinuation
- 1997-04-17 AU AU25741/97A patent/AU734807B2/en not_active Ceased
- 1997-04-17 JP JP9536909A patent/JP2000508654A/ja active Pending
- 1997-04-17 CN CN97193912A patent/CN1216470A/zh active Pending
-
1998
- 1998-10-16 NO NO984851A patent/NO984851L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2251733A1 (en) | 1997-10-23 |
NO984851D0 (no) | 1998-10-16 |
EP0901375A1 (en) | 1999-03-17 |
WO1997038695A1 (en) | 1997-10-23 |
AU2574197A (en) | 1997-11-07 |
AU734807B2 (en) | 2001-06-21 |
NO984851L (no) | 1998-12-17 |
JP2000508654A (ja) | 2000-07-11 |
IL126623A0 (en) | 1999-08-17 |
CN1216470A (zh) | 1999-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peterson et al. | Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. | |
Santoli et al. | HLA-related control of spontaneous and antibody-dependent cell-mediated cytotoxic activity in humans | |
Gayraud et al. | Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. | |
Teppler et al. | Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. | |
BR112013023151A2 (pt) | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado | |
CZ281663B6 (cs) | Farmaceutický prostředek pro léčení T-buněčné leukemie (lymfomu dospělých) | |
AU2012228418A1 (en) | Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders | |
Gelfand et al. | Partial purine nucleoside phosphorylase deficiency: Studies of lymphocyte function | |
Kalayjian et al. | A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects | |
Bergamini et al. | Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding | |
Brockmeyer et al. | Immunomodulatory properties of cimetidine in ARC patients | |
US5238689A (en) | Use of ruthenium red as immunosuppressive agents | |
EP0916344A2 (en) | Nef action inhibitor | |
KR20000005539A (ko) | Dhea복합요법 | |
BEELEN et al. | Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation | |
Kaneko et al. | Role of tumour necrosis factor-alpha (TNF-α) in the induction of HIV-1 gp120-mediated CD4+ T cell anergy | |
Tenser et al. | Immunoglobulin G immunosuppression of multiple sclerosis: suppression of all three major lymphocyte subsets | |
US5122372A (en) | Process for treatment of allergies | |
WO1998047516A1 (en) | Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors | |
Hober et al. | TNF-α production by U937 promonocytes is enhanced by factors released from HIV-infected T4 lymphocytes: TNF-α is one of the mediators causing lysis of HIV-infected T4 cells | |
Bovolenta et al. | Human T-cell leukemia virus type 2 induces survival and proliferation of CD34+ TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-γ and granulocyte macrophage–colony-stimulating factor | |
CA2255856C (en) | Therapeutic uses for an aminosterol compound | |
Stavinoha et al. | Current therapy of chronic liver disease | |
Lin | Improvement in Steroid and Immunosuppressive Drug Resistant Lupus nephritis by Intravenous Prostaglandin E1Therapy | |
CN112656801A (zh) | 孕激素在治疗细胞因子释放综合征中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |